Abstract 966P
Background
Hepatocellular carcinoma (HCC) represents the third most deadly cancer worldwide with still high therapeutic failure and recurrence rates mainly associated with the late diagnosis and the molecular heterogeneity of this liver tumor. The transmembrane glycoprotein neuropilin-1 (NRP1) has shown a key role in the modulation of tumor-associated signaling pathways and processes by interacting with key receptor tyrosine kinases. Nonetheless, few studies have evaluated the potential value of NRP1 as a tumor biomarker or therapeutic target in HCC. For this reason, we aimed at assessing the clinical significance of the receptor NRP1 in the prognosis, diagnosis and other tumor-associated features in HCC patients.
Methods
We conducted a systematic review with meta-analysis including all the articles published up to May 31st 2022 that evaluated the clinical correlation of NRP1 overexpression with tumor prognosis, development and/or other clinicopathological features in patients diagnosed with HCC. An exhaustive literature search was performed in five online databases, selecting potential papers to be included based on predefined eligibility criteria. Data from included studies were extracted or estimated by Parmar method and meta-analyzed employing the STATA 16 software.
Results
A total of 1305 patients from seven studies were included in the quantitative analysis, showing approximately 53.81% of patients NRP1 overexpression. After meta-analysis, higher levels of NRP1 proved to be significantly correlated to poor prognosis, represented by lower overall survival (OS). Moreover, a significant association with tumor pathogenesis was also found by observing higher NRP1 expression in tumor tissue samples from 692 HCC patients. Finally, a marked correlation was obtained between increased NRP1 expression and patient’s age, younger than 50 years old, and a higher risk of venous invasion, highlighting the potential of NRP1 as a tumor biomarker in HCC.
Conclusions
Overall, these results suggest that NRP1 have a potential role for prognosis, development and risk of invasion, and, therefore, could constitute a valuable biomarker in patients diagnosed with HCC.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
CIBERehd is funded by Instituto de Salud Carlos III (ISCIII), Spain.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
990P - Prognosis prediction for unresectable hepatocellular carcinoma undergoing hepatic arterial infusion chemotherapy using convolutional neural network model
Presenter: bing quan
Session: Poster session 18
991P - Real-world comparison of trans-arterial chemoembolization and bland embolization for the treatment of hepatocellular carcinoma: A propensity score analysis
Presenter: Allan Ramos-Esquivel
Session: Poster session 18
993P - Thyroid dysfunction after atezolizumab and bevacizumab is associated with favorable outcomes in hepatocellular carcinoma (IMbrave150 and Korean patients cohorts)
Presenter: Hongjae Chon
Session: Poster session 18
995P - Real-world treatment patterns, survival and costs in advanced hepatocellular carcinoma (aHCC) in Ontario, Canada
Presenter: Dominick Bossé
Session: Poster session 18
996P - Transarterial chemoembolization combined donafenib with/without programmed death-1 inhibitors for initially unresectable hepatocellular carcinoma in a multicenter retrospective study
Presenter: Xuhua Duan
Session: Poster session 18
998P - Efficacy and safety of curative hepatectomy after conversion therapies for initial unresectable hepatocellular carcinoma: A multicenter propensity score matching study
Presenter: Rong-yun Mai
Session: Poster session 18